Hemophilia A Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hemophilia A Epidemiology Forecast Report Coverage

Expert Market Research's “Hemophilia A Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of hemophilia A. It projects the future incidence and prevalence rates of hemophilia A cases across various populations. The study covers age, gender, and type as major determinants of the hemophilia A population. The report highlights patterns in the prevalence of hemophilia A overtime and projects future trends based on multiple variables.

Hemophilia A Understanding: Disease Overview

Hemophilia A is a rare X-linked recessive condition caused by a deficiency or absence of clotting factor VIII (FVIII). It primarily affects males, while females are typically carriers. People with hemophilia A are susceptible to spontaneous bleeding episodes and prolonged bleeding after injuries, surgery, or dental work. Common symptoms include easy bruising, joint swelling, and internal bleeding. Based on the FVIII levels and severity of the bleeding episodes, hemophilia A is classified as severe, moderate, and mild. Severe hemophilia A cases are reported to be characterized by frequent spontaneous bleeding into muscles and joints.

Hemophilia A Epidemiology Perspective

The hemophilia A epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hemophilia A epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hemophilia A and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Hemophilia A accounts for approximately 85% of all hemophilia cases globally, remaining the most prevalent subtype of this inherited bleeding disorder.
• The prevalence of Hemophilia A is estimated at ~17.1 cases per 100,000 males, based on recent WHO-supported epidemiological analysis.
• The incidence at birth is approximately 24.6 cases per 100,000 male births, reflecting consistent global occurrence rates across populations.
• According to the Centers for Disease Control and Prevention, Hemophilia A occurs 3 to 4 times more frequently than Hemophilia B, confirming its dominant clinical distribution.
• Hemophilia A remains the most common X-linked inherited bleeding disorder, with the majority of cases occurring in males, although approximately 5% of identified cases are females, often presenting with milder or atypical symptoms.

Read more about this report - Request a Free Sample

Country-wise Hemophilia A Epidemiology Segment

The hemophilia A epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country-wise epidemiological trends of Hemophilia A reflect variations in diagnosis and registry systems, highlighting hemophilia A prevalence patterns across regions. For instance, in the United States, according to the Centers for Disease Control and Prevention, approximately 12 per 100,000 males are affected, with around 400 new cases reported annually. Additionally, in Japan, a nationwide survey identified 8,751 coagulation disorder cases, including 5,301 Hemophilia A patients. These findings indicate a comparatively higher absolute burden in the U.S., while Japan demonstrates structured registry-based disease tracking and reporting systems.

Hemophilia A: Treatment Overview

Hemophilia A treatment focuses on controlling bleeding episodes and preventing long-term complications, reflecting advancements in the hemophilia A treatment landscape. Factor replacement therapy remains the cornerstone, involving intravenous administration of factor VIII (FVIII) concentrates, often used prophylactically to prevent spontaneous bleeding and joint damage. Desmopressin (DDAVP) is effective in mild cases by promoting endogenous FVIII release. Emerging therapies, including gene therapy, aim to provide sustained clinical benefit. Notably, in December 2023, the U.S. Food and Drug Administration approved Alhemo for reducing bleeding episodes in patients aged 12 and older with inhibitors.

Key Questions Answered

• What are the key findings of hemophilia A epidemiology in the 8 major markets?
• What will be the total number of patients with hemophilia A across the 8 major markets during the forecast period?
• What was the country-wise hemophilia A epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hemophilia A patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hemophilia A during the forecast period of 2026-2035?
• What are the currently available treatments for hemophilia A?
• What are the disease risks, signs, symptoms, and unmet needs of hemophilia A?

Scope of the Hemophilia A Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hemophilia A based on several factors.
• Hemophilia A Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hemophilia A report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Hemophilia Epidemiology Forecast

Hemophilia Market